Seres Therapeutics (MCRB) Leases: 2019-2025
Historic Leases for Seres Therapeutics (MCRB) over the last 7 years, with Sep 2025 value amounting to $74.7 million.
- Seres Therapeutics' Leases fell 9.94% to $74.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.7 million, marking a year-over-year decrease of 9.94%. This contributed to the annual value of $80.9 million for FY2024, which is 10.52% down from last year.
- Latest data reveals that Seres Therapeutics reported Leases of $74.7 million as of Q3 2025, which was down 2.77% from $76.8 million recorded in Q2 2025.
- Over the past 5 years, Seres Therapeutics' Leases peaked at $111.0 million during Q4 2022, and registered a low of $8.4 million during Q1 2021.
- For the 3-year period, Seres Therapeutics' Leases averaged around $92.8 million, with its median value being $90.4 million (2023).
- Per our database at Business Quant, Seres Therapeutics' Leases spiked by 509.53% in 2022 and then declined by 25.65% in 2025.
- Over the past 5 years, Seres Therapeutics' Leases (Quarterly) stood at $18.2 million in 2021, then surged by 509.53% to $111.0 million in 2022, then dropped by 18.53% to $90.4 million in 2023, then dropped by 10.52% to $80.9 million in 2024, then declined by 9.94% to $74.7 million in 2025.
- Its Leases stands at $74.7 million for Q3 2025, versus $76.8 million for Q2 2025 and $78.9 million for Q1 2025.